QUIA PHARMA AB (STU:99B0) Total Operating Expense: €2.46 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:99B0 QUIA PHARMA AB STU:99B0
4 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is QUIA PHARMA AB Total Operating Expense?

QUIA PHARMA AB STU:99B0 4 Total Operating Expense is €2.46 Mil as of Jun. 2025. GuruFocus rates STU:99B0 with a GF Score™ of 4/100. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's Total Operating Expense for the six months ended in Jun. 2025 was €0.54 Mil. QUIA PHARMA AB's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was €2.46 Mil.

QUIA PHARMA AB Total Operating Expense Related Terms

QUIA PHARMA AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Total Operating Expense Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.16 1.74 1.74 1.58 3.11

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.82 0.62 1.92 0.54
STU:99B0
4GF Score
QUIA PHARMA AB STU:99B0
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

QUIA PHARMA AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €2.46 Mil mean?
QUIA PHARMA AB (STU:99B0) has a Total Operating Expense of €2.46 Mil as of Jun. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Total Operating Expense too high?
QUIA PHARMA AB's current Total Operating Expense is €2.46 Mil. Overall, QUIA PHARMA AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does QUIA PHARMA AB's Total Operating Expense compare to VRTX and REGN?
QUIA PHARMA AB's Total Operating Expense of €2.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Total Operating Expense is €2.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (STU:99B0) has a current Total Operating Expense of €2.46 Mil. The current Total Operating Expense is €2.46 Mil. QUIA PHARMA AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For QUIA PHARMA AB (STU:99B0), the current Total Operating Expense is €2.46 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.
4GF Score

Get the complete analysis for STU:99B0

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price